Pocket guide: biologics in upper and lower airways in adults

The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.

Authors

Institutions

Publication Details

Journal
Rhinology Journal
Published
2025-03-01
DOI
https://doi.org/10.4193/rhin24.510
Citations
4
Primary Topic
Pediatric health and respiratory diseases
Type
article
Field-Weighted Citation Impact
10.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pocket guide: biologics in upper and lower airways in adults

Manuel Bernal‐Sprekelsen, Sven Schneider, S.E. Lee, Marjolein Cornet et al.
4 citations
Rhinology Journal
Pediatric health and respiratory diseases
10.07
article

Pocket guide: biologics in upper and lower airways in adults

Manuel Bernal‐Sprekelsen, Sven Schneider, S.E. Lee, Marjolein Cornet, Santiago Quirce, Peter W. Hellings, Basile N. Landis, Peter J. Barnes, Dermot Ryan, Michael E. Wechsler, Guy Joos, Mina Gaga, Zuzana Diamant, V. Backer, Ratko Djukanović, Eugenio De Corso, J K Han, Anju T. Peters, Susanne Lau, Diego M. Conti, Brent A. Senior, Ian Pavord, Claire Hopkins, G K Scadding, Philippe Gevaert, Valerie Lund, L. Bjermer, Joaquim Mullol, W. J. Fokkens
article en
4 citations

Abstract

The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.

Rhinology JournalVol. 0(0)
Northwestern University (US), Eastern Virginia Medical School (US), King's College London (GB), Lund University (SE), National Jewish Health (US), Ghent University (BE), University of Oxford (GB), Alrijne Ziekenhuis (NL), Hygeia Hospital (GR), European Federation of Allergy and Airways Diseases Patients Associations (BE), Royal National Throat Nose and Ear Hospital (GB), Skåne University Hospital (SE), University College London (GB), Charité - Universitätsmedizin Berlin (DE), University of Colorado Denver (US)
Good health and well-being
Openalex Percentile: Top 2%
Pediatric health and respiratory diseases
10.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.